Despite the small number of patients, 13 patients with prior BCMA-ADC and 7 patients with prior BCMA-bispecific antibody, these findings suggested that cilta-cel might be considered a viable option for select heavily pretreated MM patients who received prior BCMA-directed therapies, namely anti-BCMA ADC. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.